Two oncolytic adenoviruses were evaluated in this work: the E1A CR2-deleted Ad5 mutant dl922-947, which we have previously shown has significant efficacy in ovarian cancer models,9,10 and the chimeric Ad3/Ad11p mutant enadenotucirev, which was generated by directed evolution11 and is currently being tested in early phase clinical trials in ovarian (ClinicalTrials.gov: NCT02053220)12 and other cancers (ClinicalTrials.gov: NCT02028117). This evidence concerns the gene DHTKD1 and ovarian cancer.